

Ashwin S Nathan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5854570/publications.pdf>

Version: 2024-02-01

51
papers

1,566
citations

471509

17
h-index

330143

37
g-index

51
all docs

51
docs citations

51
times ranked

1934
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. <i>JAMA Cardiology</i> , 2022, 7, 150.	6.1	37
2	Economic Considerations in Access to Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011489.	3.9	8
3	Rural-Urban Disparities in Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2022, 79, 280-282.	2.8	4
4	Percutaneous Coronary Intervention in Acute Coronary Syndrome and Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 887-889.	2.9	2
5	Association Between Community-Level Violent Crime and Cardiovascular Mortality in Chicago: A Longitudinal Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
6	Observational study assessing changes in timing of readmissions around postdischarge day 30 associated with the introduction of the Hospital Readmissions Reduction Program. <i>BMJ Quality and Safety</i> , 2021, 30, 493-499.	3.7	2
7	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. <i>American Heart Journal</i> , 2021, 232, 1-9.	2.7	6
8	Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation. <i>JAMA Network Open</i> , 2021, 4, e210247.	5.9	48
9	Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 445.	7.4	24
10	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e019331.	3.7	19
11	Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006887.	2.2	2
12	Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010032.	3.9	23
13	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. <i>JAMA Network Open</i> , 2021, 4, e216139.	5.9	187
14	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. <i>Circulation: Heart Failure</i> , 2021, 14, e008277.	3.9	1
15	Reporting of Percutaneous Coronary Interventions Site-Specific Mortality—Reply. <i>JAMA Cardiology</i> , 2021, 6, 1344.	6.1	0
16	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010750.	3.9	0
17	Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. <i>Journal of the American Heart Association</i> , 2021, 10, e021456.	3.7	42
18	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012–2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008260.	2.2	27

#	ARTICLE	IF	CITATIONS
19	Current interventional therapies in acute pulmonary embolism. <i>Progress in Cardiovascular Diseases</i> , 2021, 69, 54-61.	3.1	3
20	Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2213-2217.	2.8	1
21	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. <i>JAMA Health Forum</i> , 2021, 2, e214182.	2.2	58
22	The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19. <i>Journal of the American Heart Association</i> , 2020, 9, e018274.	3.7	14
23	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009179.	3.9	9
24	Establishing an Interdisciplinary Research Model Among Trainees. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2565-2568.	2.8	5
25	Telemedicine Outpatient Cardiovascular Care During the COVID-19 Pandemic. <i>Circulation</i> , 2020, 142, 510-512.	1.6	188
26	Mortality trends around the one-year survival mark after heart, liver, and lung transplantation in the United States. <i>Clinical Transplantation</i> , 2020, 34, e13852.	1.6	3
27	Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002640.	3.6	39
28	Deriving Function From Structure. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 498-501.	2.9	2
29	Outcomes of catheter-directed versus systemic thrombolysis for the treatment of pulmonary embolism: A real-world analysis of national administrative claims. <i>Vascular Medicine</i> , 2020, 25, 334-340.	1.5	23
30	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 765.	6.1	10
31	Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2031640.	5.9	494
32	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009975.	3.9	1
33	Paving a Road to PCI Quality With Good Intentions and Rigorous Statistics. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1976-1978.	2.9	0
34	Association of Medicaid Expansion With Cardiovascular Mortality. <i>JAMA Cardiology</i> , 2019, 4, 671.	6.1	102
35	Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007564.	3.9	7
36	Centers of Excellence Designations, Clinical Outcomes, and Characteristics of Hospitals Performing Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2019, 179, 1138.	5.1	5

#	ARTICLE	IF	CITATIONS
37	Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005600.	2.2	42
38	Reexamining the Open-Vein Hypothesis for Acute Deep Venous Thrombosis. <i>Circulation</i> , 2019, 139, 1174-1176.	1.6	14
39	The Pros and Cons of Percutaneous Coronary Intervention in Patients With Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 156-158.	4.0	0
40	The Lotus Valve System: an In-depth Review of the Technology. <i>Current Cardiology Reports</i> , 2019, 21, 157.	2.9	7
41	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 17.	0.9	1
42	Is it Time to Abandon Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation on Anticoagulation?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 635-637.	2.9	2
43	Association Between 30-Day Mortality After Percutaneous Coronary Intervention and Education and Certification Variables for New York State Interventional Cardiologists. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006094.	3.9	4
44	Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1587-1589.	2.9	1
45	Bioresorbable Scaffolds for Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 5.	2.9	4
46	Nitinol Self-Expanding Stents for the Superficial Femoral Artery. <i>Interventional Cardiology Clinics</i> , 2017, 6, 227-233.	0.4	6
47	How Should We Address Carotid Artery Stenosis Around the Time of Open-Heart Surgery?. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 299-301.	2.9	2
48	Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation. <i>American Heart Journal</i> , 2017, 189, 184-192.	2.7	47
49	Too Hot? Too Cold? When Is it "Just Right" to Stop Dual Antiplatelet Therapy After PCI With DES?. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1631-1632.	2.9	1
50	Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. <i>Current Atherosclerosis Reports</i> , 2017, 19, 56.	4.8	16
51	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 134, 989-998.	1.6	19